Q2 2020 Cytokinetics Inc Earnings Call Transcript
Good afternoon, and welcome, ladies and gentlemen, to the Cytokinetics Second Quarter 2020 Conference Call. At this time, I'd like to inform you that this call is being recorded (Operator Instructions). At the company's request, we will open the call for questions and answers after the presentation.
I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks for joining us on the call today.
Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and our recent progress. Then Fady Malik, our EVP of Research and Development, will provide updates on key developments for omecamtiv mecarbil, our cardiac myosin activator being developed under our collaboration with Amgen, and the expanded and accelerated development plan for CK-274, our next in class cardiac myosin inhibitor. Next,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |